Page 9 - Pharma Stocks

Pharma funds remain in poor health amid headwinds on compliance

The BSE Healthcare Index has fallen 10 per cent in the last one year

Lupin, Divi's Lab, Aurobindo Pharma: Here's how you can trade pharma stocks

A major bullish trend may start only above the range of 8,600 - 8,500 level, that said it seems far considering the resistance of 8,400 level.

Pharma sector likely to bounce back in 2019 after three years of slump

Stability in pricing for the second consecutive quarter may bring back buoyancy

From Sun Pharma to Lupin, pharma stocks rally on quarterly show

Companies put up stellar performance in Indian as well as US markets

Re-rating likely of pharma stocks

The BSE Healthcare index has been one of the biggest gainers over the past few days, on easing of regulatory concerns, improving visibility over product launches and a return of growth in the domestic market.Ranjit Kapadia of Centrum Broking believes there are encouraging signs which could lead to a re-rating of pharmaceutical stocks, on the back of re-stocking in India and some recovery in the American market. Earlier, most analysts had thought there would be no revenue growth in the US market for large generic players for at least a year. The expected recovery there, led by niche product launches and regulatory clearances for affected plants, could now start in the March quarter of FY18, instead of FY19. Barring Cipla, the top five Indian pharma companies by market capitalisation get upwards of 40 per cent of their revenue from the US market. The key trigger for the segment has been the recent regulatory clearances for factories here, earlier pulled up for not meeting the US Food ..

Pharma stocks on mutual funds' radar post price correction

Domestic mutual funds (MFs) have taken a liking to pharmaceutical stocks, following a steep fall in the latter's prices.While they expect the pharma sector to undergo headwinds, they are taking a contrarian view on select stocks, with an investment horizon of two to three years. Sun Pharmaceutical, Apollo Hospital Enterprise, Dr Reddy's Laboratories, Aurobindo Pharma and Fortis Healthcare were among the most-bought stocks in the month of May by fund managers. Last month, Divi's Laboratories, along with Aurobindo and Fortis Healthcare, were the top picks.S Naren, chief investment officer (CIO) at ICICI Prudential MF, says, "India's pharmaceutical companies have been under intense scrutiny from the US Food and Drug Administration (FDA) over the past few years. This has led to considerable price erosion. With popularity of this sector at a multi-year low, the ownership of stocks in the sector saw a steep decline. We believe, at the current juncture, the (share of the) sector is largely ..

Fund managers make contrarian bets on pharma stocks

Sun Pharma emerged as top choice since equity mutual funds added about 15 mn shares to portfolio

Pharma stocks decline on fears of new US order, competition

Pharmaceutical sector stocks slipped on Friday, following adverse observations from the US regulator, the Food and Drug Administration (FDA), increased competition and fears of a new pricing policy in the US.The BSE healthcare index declined 1.5 per cent on Friday. On a year to date basis, it (comprising 69 companies) is down nearly four per cent, while the overall benchmark has risen 16-17 per cent.IPCA Laboratories was the biggest loser, with the US having banned drug import from its three plants. The stock fell a little over 15 per cent in intra-day trade but recovered to close eight per cent lower at Rs 471.70. Its plants in Madhya Pradesh and Silvassa were under a US import alert since 2014 and 2015, respectively; the company was exporting limited products, exempted from the ban. On Thursday, the company said the FDA had withdrawn those exemptions.Lupin's stock fell 4.4 per cent, after Aurobindo Pharma received approval for the first generic version of Renvela, used for ...

Despite fall, muted FY18 outlook will keep pharma stocks under pressure

Company expects a single-digit decline in FY18 revenues, which took Street by surprise

Nifty Pharma index at three-year low; what's ailing pharma stocks?

Shares of pharmaceutical companies came under pressure on Tuesday with the Nifty Pharma index slipping nearly 3% to hit a 52-week low of 9,528.95 in intra-day deals, its lowest level since August 18, 2014 on the National Stock Exchange (NSE).On the Bombay Stock Exchange (BSE) the S&P BSE Healthcare index, too, dipped nearly 3% or 429 points to 14,184 levels. By comparison, the benchmark indices, Nifty50 and the S&P BSE Sensex were trading 0.5% lower, respectively.Thus far in the calendar year 2017, the Nifty Pharma index has underperformed with a fall of nearly 6%, as compared to a rally of around 15% in the Nifty50 and the S&P BSE Sensex.Among individual stocks, Lupin, Aurobindo Pharma, Divi's Laboratories, Glenmark Pharmaceuticals, Indoco Remedies, Strides Shasun and Wockhardt hit their respective 52-week low on the BSE in intra-day trade on Tuesday.So what's ailing pharma stocks?Indian pharma stocks have de-rated by 10% over the last one year, but with product price ...